Immunocore Holdings Ltd (IMCR) - Total Assets
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) holds total assets worth $1.10 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immunocore Holdings Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's total assets have evolved over time, based on quarterly financial data. Also see Immunocore Holdings Ltd market capitalisation for the company's overall valuation and market capitalisation.
Immunocore Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Immunocore Holdings Ltd's total assets of $1.10 Billion consist of 92.1% current assets and 7.9% non-current assets. Review Immunocore Holdings Ltd debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.1% |
| Accounts Receivable | $83.10 Million | 8.2% |
| Inventory | $5.45 Million | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Immunocore Holdings Ltd (IMCR) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunocore Holdings Ltd's current assets represent 92.1% of total assets in 2024, an increase from 87.4% in 2018.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, down from 63.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 8.2% of total assets.
Immunocore Holdings Ltd Competitors by Total Assets
Key competitors of Immunocore Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Immunocore Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.00 | 3.78 | 2.78 |
| Quick Ratio | 5.97 | 3.76 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $852.50 Million | $739.66 Million | $97.93 Million |
Immunocore Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Immunocore Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.12 |
| Latest Market Cap to Assets Ratio | 1.59 |
| Asset Growth Rate (YoY) | 69.1% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $1.61 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Immunocore Holdings Ltd's assets above their book value (1.59x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Immunocore Holdings Ltd's assets grew by 69.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual total assets of Immunocore Holdings Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.01 Billion | +69.10% |
| 2023-12-31 | $597.00 Million | +13.33% |
| 2022-12-31 | $526.76 Million | +29.34% |
| 2021-12-31 | $407.28 Million | +106.54% |
| 2020-12-31 | $197.19 Million | -19.82% |
| 2019-12-31 | $245.94 Million | +25.62% |
| 2018-12-31 | $195.78 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more